ARQT · Arcutis Biotherapeutics, Inc.

Track ARQT — free

$26.34 -0.09 (-0.34%)

S&P 600 member Russell 2000 member Rebalance outlook locked

Market Cap

$3.39B

125.69M

Volume · Sep 30 2.39M Avg daily vol (3M) 2.18M

Up next

Next earnings call

Oct 31, 2026 Est · unconfirmed · in 4 wks

Latest filing: 10-Q

filed Aug 5, 2026

Q2 2026 earnings call transcript

call held Aug 5, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$463.98M

Trailing 12 months

Net income (TTM)

$28.52M

Trailing 12 months

Revenue growth YoY

+59.3%

Year over year

Operating margin

7.4%

Trailing 12 months

P / E (TTM)

121.6

Trailing earnings · reciprocal yield 0.8%

FCF yield

1.2%

TTM · current market cap

Return on invested capital

11.3%

Trailing 12 months

Net cash

−$74.78M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+7.0%

Year over year · more shares

Price change (1Y)

+43.7%

Trailing year

Short interest

14.7%

Latest settlement · 8.5 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Buy Momentum Neutral Sentiment Neutral Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 16.3 · calm Equity put/call 0.53

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +5%

above

Price vs 50-day avg +2%

above

RSI (14) 54

neutral

MACD trend Positive

52-week position 61%

mid-range

Momentum

relative strength

Neutral

1-month return +11%

trailing

6-month return +8%

trailing

YTD return −9%

this year

Relative strength −5%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $26 › 200d $25 — 50d above 200d

Institutional flow Accumulating

+1% holders QoQ · +41 funds added

Insider flow Distributing

Net -$1.4M over 90 days · 100% sells

Short interest Rising

14.69% of float · ▲ +11.5% MoM · 8.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

272 holders — mid 3-yr range

Squeeze score 73

high risk · 0–100

Fundamentals

Fair

Revenue growth +91%

Y/Y

EPS growth +89%

Y/Y

Free cash flow $-6.3M

Balance sheet $66.1M

net debt

Quant / Vol

risk profile

Very High

Volatility 57%

annualized · 1-yr

Max drawdown −38%

past year

ATR 4.8%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Aug 5, 2026

Net product sales · full year 2026 Initiated $525M – $540M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

0 · 3 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+5% Bullish

Price vs 50-day avg

+2% Bullish

RSI (14)

54 Neutral

MACD trend

Positive Bullish

52-week position

61% Neutral

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $26 › 200d $25 — 50d above 200d

Institutional flow Accumulating

+1% holders QoQ · +41 funds added

Insider flow Distributing

Net -$1.4M over 90 days · 100% sells

Short interest Rising

14.69% of float · ▲ +11.5% MoM · 8.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

272 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $19 Now $26 · 61% Range high $31

vs 200-day avg +5% vs 50-day avg +2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ARQT Arcutis Biotherapeutics, Inc. this stock	$3.39B	-9.0%	+91.3%	—	14.7%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+15.3%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-1.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+553.0%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

272

% held: 105.0%
Net QoQ: -759.2K sh
Top holder: SUVRETTA CAPITAL MANAGEME…

Held Float

View

Held by Funds

Fund positions

228

View

Short & Settlement

Short Interest Rising

Shares short

18.5M

Days to cover: 8.5d
Change: +1.9M sh

View

Short Volume

Short vol %

56%

As of: Sep 30, 2026

Short Total

View

Fails to Deliver

FTD shares

803

Value: $19.2K
As of: Sep 3, 2026

View

Off-Exchange

Off-exchange %

50.5%

Week of: Aug 24, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$1.4M

Buyers / Sellers: 0 / 2

Buyers Sellers

View

Congressional Trades Buy

Member

Gilbert Cisneros

Amount: $1.0K–$15.0K
Traded: May 29, 2026

View

Financials

Revenue (FY)

$376.1M

Net income (FY): $-16.1M
EPS diluted: $-0.13

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Sep 16, 2026
This year: 13

View

Proposed Sales

Value

$238.8K

Shares: 10.0K
Filed: Apr 1, 2026

View

Earnings & Events

Earnings Calls

Last call

Sep 16, 2026

View

Performance

	5D	20D	120D	MTD	YTD
ARQT	+0.2%	+11.3%	+7.6%	+10.3%	-9.0%
SPY	-0.7%	+0.1%	+12.2%	-0.6%	+11.8%
vs SPY	+0.9%	+11.2%	-4.6%	+10.8%	-20.8%

Key facts CIK 1787306 CUSIP 03969K108 13F (30d) 8 filings 7 filers Visit website Investor relations

ARQT · Arcutis Biotherapeutics, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance